Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDB-001 in ANCA-Associated Vasculitis
NCT07168161Phase 3Recruiting
- Sponsor
- Staidson Biopharmaceutical
- Start
- Nov 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of BDB-001 in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Staidson Biopharmaceutical. Started Nov 2025; status: recruiting.
02
Drugs
BDB-001
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07168161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168161.